Key result
Single endopeptidase treatment of bovine heart hydrolysates yields ~69% ACE-I inhibition and strong neprilysin inhibition.
Why the study?
Valorisation of meat by-products as functional ingredients is gaining attention for sustainable protein recovery, motivating the exploration of bovine heart hydrolysates as sources of antihypertensive peptides.
Does enzymatic hydrolysis of bovine heart produce peptides that inhibit ACE-I and neprilysin in vitro?
Does enzymatic hydrolysis of bovine heart produce peptides that inhibit ACE-I and neprilysin in vitro?
Bovine heart hydrolysates produced via single endopeptidase treatments exhibit significant in vitro ACE-I and neprilysin inhibitory activity, suggesting potential as functional food ingredients for cardiovascular health.
Answers are grounded in this paper and cite their sources.
Should not yet change antihypertensive therapy; leaves open sustainable production of ACE-I peptides from meat by-products.
The valorisation of meat by-products as sources of functional ingredients is gaining attention due to interest in sustainable protein recovery. This study explored the generation of antihypertensive peptides from bovine heart hydrolysates produced using Novozym®, Protamex®, and their combinations with the exopeptidase Protana™ Prime. Sequential enzyme treatments increased hydrolysis and amino acid release, while single endopeptidases yielded higher angiotensin-converting enzyme-I (ACE-I) and neprilysin (NEP) inhibitory activities, reaching 68.72% in the Protamex hydrolysate and 58.48% in the Novozym hydrolysate, respectively. Peptide profiling by LC–MS/MS identified 1251 peptides in the most bioactive fraction, mainly derived from muscle proteins. In silico analysis with PeptideRanker predicted 172 peptides with high bioactivity, whereas AHTpin supported antihypertensive activity for 109 peptides. MultiPep predicted ACE-inhibitory activity for NPPKFDK, VYPFPGPI, and VYPFPGPIPN, the latter showing the highest antihypertensive score (0.995). Additionally, KPPVVKW, LKPLPPK, and LKPRPPAR showed cell-penetrating peptide scores > 0.6, suggesting potential for cellular uptake. This study represents one of the first reports of NEP-inhibitory activity in bovine-derived peptides, highlighting heart hydrolysates as promising sources of multifunctional peptides for use in functional foods or nutraceuticals targeting cardiovascular health.
No takes yet. Share an insight, caveat, or question.
Kralj et al. (2026) studied Hypertension (in vitro model). Bovine heart hydrolysates (Novozym, Protamex, Protana Prime) vs. Control (unhydrolysed sample) was evaluated on ACE-I inhibitory activity. Single endopeptidase treatments of bovine heart hydrolysates yielded high ACE-I and neprilysin inhibitory activities, reaching 68.72% and 58.48% respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: